Adicet Bio (ACET) Revenue (2019 - 2022)

Adicet Bio has reported Revenue for 4 years, with the latest figure at $25.0 million in Q1 2022.

• On a quarterly basis, Revenue rose 527.73% year-over-year to $25.0 million in Q1 2022; TTM through Dec 2022 was $25.0 million, a 41.25% increase from a year earlier, with the FY2022 full-year figure at $25.0 million, up 156.83% from the prior year.
• Revenue was $25.0 million for Q1 2022 at Adicet Bio, up from $5.5 million in the prior quarter.
• The five-year high for Revenue was $25.0 million in Q1 2022, with the low at $21000.0 in Q4 2019.
• Average Revenue over 4 years is $6.2 million, with a median of $4.8 million recorded in 2021.
• The largest YoY upside for Revenue was 25661.9% in 2020 against a maximum downside of 57.03% in 2020.
• Over 4 years, Revenue stood at $21000.0 in 2019, then soared by 25661.9% to $5.4 million in 2020, then advanced by 1.07% to $5.5 million in 2021, then soared by 357.02% to $25.0 million in 2022.
• The last three Revenue figures came in at $25.0 million (Q1 2022), $5.5 million (Q4 2021), and $3.4 million (Q3 2021), per Business Quant data.